Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The epigenetic landscape of human colorectal cancer

ABSTRACT: The epigenetic landscape of human colorectal cancer

PROVIDER: PRJEB34779 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

The epigenetic landscape of human colorectal cancer

Project description:The epigenetic landscape of human colorectal cancer

| PRJEB34931 | ENA

The epigenetic landscape of human colorectal cancer

Project description:We characterized the epigenetic landscape of human colorectal cancer (CRC). To this extent, we performed gene expression profiling using high throughput sequencing (RNA-seq) and genome wide binding/occupancy profiling (ChIP-seq) for histone modifications correlated to transcriptional activity, enhancers, elongation and repression (H3K4me3, H3K4me1, H3K27Ac, H3K36me3, H3K27me3) in patient-derived organoids (PDOs), and in normal and tumoral primary colon tissues. We also generated ChIP-seq data for transcription factors YAP/TAZ in human CRC PDOs.

2021-02-23 | E-MTAB-8416 | biostudies-arrayexpress

The epigenetic landscape of human colorectal cancer

2021-03-10 | E-MTAB-8448 | biostudies-arrayexpress

Epigenetic Profiling of Human Colorectal Cancer

Project description:Epigenetic Profiling of Human Colorectal Cancer

| PRJNA75343 | ENA

Epigenomics landscape of colorectal cancer

Project description:Epigenomics landscape of colorectal cancer

| PRJNA563919 | ENA

Genomic landscape of metastatic colorectal cancer

Project description:Response to drug therapy in individual colorectal cancer (CRC) patients is associated with tumor biology. Here we describe the genomic landscape of tumor samples of a homogeneous well-annotated series of patients with metastatic CRC of two phase III clinical trials, CAIRO and CAIRO2. DNA copy number aberrations of 349 patients are determined. Within three treatment arms, 194 chromosomal sub-regions are associated with progression free survival PFS (uncorrected single-test p-values < 0.005). These sub-regions are filtered for effect on mRNA expression, using an independent data set from The Cancer Genome Atlas (TCGA) which returned 171 genes. Three chromosomal regions are associated with a significant difference in PFS between treatment arms with or without irinotecan. One of these regions, 6q16.1-q21, correlates in vitro with sensitivity to SN-38, the active metabolite of irinotecan. This genomic landscape of metastatic CRC reveals a number of DNA copy number aberrations associated with response to drug therapy. aCGH data of colorectal cancers of patients from 2 clinical trials (CAIRO, CAIRO2). 105 patients were treated with capecitabine first line (CAIRO arm A), 111 patients were treated with capecitabine and irinotecan first line (CAIRO arm B), and 133 patients were treated with capecitabine, oxaliplatin and bevacizumab (CAIRO2 arm A).

2014-11-14 | E-GEOD-36864 | biostudies-arrayexpress

ChIP-seq dataset for epigenomics landscape of colorectal cancer

Project description:ChIP-seq dataset for epigenomics landscape of colorectal cancer

| PRJNA563925 | ENA

Hi-ChIP dataset for epigenomics landscape of colorectal cancer

Project description:Hi-ChIP dataset for epigenomics landscape of colorectal cancer

| PRJNA562895 | ENA

Colorectal cancer

Project description:Colorectal cancer

| PRJNA774637 | ENA

AOM/DSS colorectal cancer mouse epigenetic landscape in the progression of colites to tumor [ChIP-seq]

Project description:AOM/DSS colorectal cancer mouse epigenetic landscape in the progression of colites to tumor [ChIP-seq]